Elite Pharmaceuticals, Inc. (ELTP)
| Market Cap | 372.76M |
| Revenue (ttm) | 140.12M |
| Net Income (ttm) | 43.41M |
| Shares Out | 1.08B |
| EPS (ttm) | 0.04 |
| PE Ratio | 9.72 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,711 |
| Average Volume | 402,937 |
| Open | 0.360 |
| Previous Close | 0.350 |
| Day's Range | 0.342 - 0.362 |
| 52-Week Range | 0.340 - 0.819 |
| Beta | 0.44 |
| RSI | 36.27 |
| Earnings Date | Jun 30, 2026 |
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; P... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, to...
Elite Pharmaceuticals Earnings Call Transcript: Q3 2026
Record Q3 and nine-month results with revenue and profit more than doubling year-over-year, driven by strong market share in key generics and new product launches. Outlook remains positive with further launches and R&D investment planned.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"),...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
Financials for Third Quarter of Fiscal Year 2026 Ended December 31, 2025 will be released on Tuesday, February 17, 2026 Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceutic...
Elite Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 FY2026 revenue nearly doubled year-over-year, driven by strong lisdexamfetamine sales and expanding market share in key products. Margins declined due to competition and one-time costs, but cash flow and balance sheet strength improved. M&A remains a strategic focus.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Conference Call Scheduled for Monday, November 17 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025 Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuti...
Elite Pharmaceuticals Earnings Call Transcript: Q1 2026
Record quarterly revenue and profit growth driven by Lisdex and Elite label products, with strong cash flow and working capital. Margins are expected to decline as competition intensifies, but market share and product pipeline remain robust.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a spec...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025
Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, August 14, 2025 Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc...
Elite Pharmaceuticals Earnings Call Transcript: Q4 2025
Fiscal 2025 saw 52% revenue growth to $84 million and an 82% rise in operating income, driven by strong launches and expanding market share in key generics. The company is prioritizing M&A, maintaining low debt, and advancing a robust product pipeline.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, July 1 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialt...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025 Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ...
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufactu...
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, t...
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, an...
Elite Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 revenue declined 8% year-over-year due to shipment delays, but nine-month revenue rose 35% and January saw record shipments. Major launches, including generic Vyvanse, position the company for a record year with over $70M in revenue expected.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025 Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmac...
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products...
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products,...
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manuf...
Elite Pharmaceuticals Earnings Call Transcript: Q2 2025
Record revenue and profit growth continued, with $18.9M in quarterly revenue and $7.3M year-to-date profit. Strong cash flow and working capital support a robust pipeline, with multiple product launches and facility expansion positioning for further growth.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharma...